Product Description
(Halobetasol Propionate) Foam, 0.05% is indicated for the topical treatment of plaque psoriasis in patients eighteen (18) years of age and older.
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Therapeutics, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Psoriasis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01698333 |
NCT01698333 | P2 |
Completed |
Psoriasis |
2013-03-01 |
2019-03-19 |
Treatments |
|
NCT01700985 |
NCT01700985 | P2 |
Completed |
Psoriasis |
2012-09-01 |
2019-03-19 |
Treatments |
|
NCT02742441 |
Study 310 | P3 |
Completed |
Psoriasis |
2017-02-27 |
2019-03-20 |
Treatments |
|
NCT02367911 |
NCT02367911 | P3 |
Completed |
Psoriasis |
2015-08-01 |
2019-03-20 |
Treatments |
|
NCT02368210 |
Study 306 | P3 |
Completed |
Psoriasis |
2015-06-01 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|